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Purpose: The purpose of this study was to develop a novel cancer vaccine using the targeting 
system of antigen protein to antigen-presenting cells (APCs) for efficient and safe cancer 
therapy. 
Methods: The novel delivery system was constructed with antigen protein, benzalkonium 
chloride (BK), and γ-polyglutamic acid (γ-PGA).  In this experiment, we used ovalbumin 
(OVA) as a model antigen protein and evaluated its immune induction effects and utilities for 
cancer vaccine.  
Results: BK and γ-PGA enabled the encapsulation of OVA and formed stable anionic particles 
at nanoscale, OVA/BK/γ-PGA complex.  The complex was taken up by the dendritic cell line 
DC2.4 cells efficiently.  We therefore subcutaneously administered the complex to mice and 
examined the induction of IgGs.  As a result, the complex induced not only Th2-type 
immunoglobulins but also Th1-type immunoglobulins.  Furthermore, the OVA/BK/γ-PGA 
complex inhibited the tumor growth of E.G7 cells expressing OVA regularly and mice 
administrated with OVA/BK/γ-PGA complex completely rejected the tumor cells.   
Conclusion: The novel vaccine could be platform technology for a cancer vaccine.  
 





 Cancer is a major global cause of morbidity and mortality, and it is expected to rise in 
coming decades (1).  Traditional treatments for cancer, such as chemotherapeutic drugs, 
radiotherapy, and interventional surgery, for solid tumor are life extending for many patients; 
however, they are rarely curative for disseminated cancers (2).   
 Many approaches for therapeutic vaccination for treating cancer have been developed 
including autologous and allogeneic tumor cells modified to express various cytokines, 
peptides, proteins, and DNA vaccines and tumor-specific immune responses could be induced 
(3).  The clinical efficacy of therapeutic vaccination in cancer is reportedly low because of 
the limited rate of objective tumor regression observed in clinical trials (4, 5). 
 Many adjuvants have been developed to improve the efficacy of these vaccines; however, 
adjuvants have been reported to cause inflammatory reactions and ulceration at the injection 
site (6-9).  Another approach to improve the efficacy of the vaccines without such adverse 
effects is to develop a vaccine delivery vector which enables delivery of the vaccine to 
antigen-presenting cells (APCs) effectively (10). 
 In the previous study, we discovered that anionic complex coated with γ-polyglutamic 
acid (γ-PGA), chondroitin sulfate, and alginic acid was taken by the cells effectively, 
regardless of the anionic surface (11, 12).  In particular, a complex of pDNA, 
polyethylenimine, and γ-PGA was taken by APCs in the spleen efficiently after its 
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administration to mice.  Furthermore, we have already demonstrated that administration of 
the malaria DNA vaccine/polyethylenimine/γ-PGA complex markedly inhibited malaria 
infection in mice (13).  So, we hypothesized that γ-PGA-coated complex containing antigen 
protein would be able to improve their immune induction effects.  Actually, there are some 
reports that γ-PGA derivatives improved the immune induction effects of antigen protein (14). 
 Several cationic compounds such as polyethylenimine, polylysine, polyarginine, chitosan, 
protamine, and benzalkonium chloride (BK) have been examined in a preliminary experiment 
to combine antigen proteins with γ-PGA; and among all those, only BK was found to connect 
OVA and γ-PGA.   
 In this experiment, we developed a new complex of γ-PGA nanoparticles with BK 
containing ovalbumin (OVA) as a model antigen protein to enhance effectiveness of cancer 
vaccine.  The prepared cancer vaccine was investigated for its in vitro and in vivo 
characterization.   
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Materials and Methods 
 
Materials 
 OVA and rhodamine B isothiocyanate (RITC) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  BK was obtained from Nacalai Tesque, Inc. (Kyoto, Japan).  The 
γ-PGA was provided by Yakult Pharmaceutical Industry Co., Ltd. (Tokyo, Japan).  Fetal 
bovine serum (FBS) was obtained from Biosource International Inc. (Camarillo, CA, USA).  
RPMI 1640, Opti-MEM I, antibiotics (penicillin 100 U/ml and streptomycin 100 μg/ml), and 
other culture reagents were obtained from GIBCO BRL (Grand Island, NY, USA).  
RITC-labeled OVA was prepared in our laboratory.  Briefly, OVA and RITC were mixed and 
stirred overnight at 4C in the dark.  RITC-labeled OVA was purified by dialysis.  
 
Preparation of vaccine 
 To prepare the OVA/BK complex, 10 μg OVA was mixed with 1, 2, and 3 μg BK; and left 
for 15 min at 4C.  To coat the OVA/BK complex with γ-PGA, 1, 2, and 3 μg γ-PGA were 
added to OVA/BK complex; and left for a further 15 min at 4C (Fig. 1).  In this experiment, 
we express the complexes with their weight ratio. 
 
Evaluation of physicochemical properties of vaccines 
 The particle size and the ζ-potential of the vaccine were measured with Zetasizer Nano 
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ZS (Malvern Instruments, Ltd., United Kingdom).  The number fractioned mean diameter is 
shown.   
 
Cells 
 DC2.4, a murine dendritic cell line, was kindly donated by Dr. Kenneth Rock 
(Department of Pathology, University of Massachusetts Medical School, MA, USA).  E.G7 
cells are OVA cDNA transfected with methylchoranthlene-induced thymoma of 
C57BL/6(H-2b) origin.  DC2.4 cells were grown in RPMI 1640 medium supplemented with 
10% heat-inactivated FBS, antibiotics, 1 mM non-essential amino acids, and 1 nM 
2-mercaptoethanol.  E.G7 cells were grown in RPMI 1640 medium supplemented with 10% 
heat-inactivated FBS, antibiotics, 1 mM non-essential amino acids, 50 μM 2-mercaptoethanol, 
and 500 μg/ml G418.  These cells were assessed under a humidified atmosphere of 5% CO2 
in air at 37C. 
 
In vitro experiments 
 DC2.4 cells were plated on 24-well collagen-containing plates (Becton-Dickinson, 
Franklin Lakes, NL, USA) at a density of 1.0 × 104 cells/well and cultivated in culture 
medium.  After 24 h preincubation, the medium was replaced with OPTIMEM I medium and 
the cells were incubated with vaccines containing 1 μg RITC-labeled OVA for 2 h.  After 
incubation, the cells were observed by fluorescent microscopy. 
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Immunization 
 Animal care and experimental procedures were performed in accordance with the 
Guidelines for Animal Experimentation of Nagasaki University with approval from the 
Institutional Animal Care and Use Committee.  Male C57BL/6Cr mice were purchased from 
Japan SLC (Shizuoka, Japan).  After shipping, mice were acclimatized to the environment 
for at least one day before the experiments.  The mice were divide into four groups of 
four-five mice and administrated weekly with 5% glucose solution, 100 μg OVA, BK/γ-PGA 
complex (vehicle), and OVA/BK/γ-PGA complex containing 100 μg OVA subcutaneously 4 
times.  Two weeks after the last immunization, blood samples were collected and serum was 
obtained.  The sera were used for ELISA assays.   
 After collections of blood samples, the mice were administrated with 1×106 E.G7 cells 
subcutaneously and tumor growth was monitored. Tumor weight (mg) was calculated as 
follows: major axis × minor axis 2 ÷ 2.  
 
Determination of OVA-specific IgG induction 
 OVA at a concentration of 10 μg/ml, in PBS, was used and 100 μl was added to each well 
of the ELISA plates (Nunc, Copenhagen, Denmark) and incubated at 4°C overnight.  The 
plates were washed five times with 0.05% Tween-20-PBS, and nonspecific binding was 
blocked using 300 μl of 0.1% blocking reagent (Roche Diagnostics, Mannheim, 
Germany) and incubated for 12 hours at 4°C.  Plates were washed three times with PBS 
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containing 0.05% Tween-20 and sera were serially diluted in the wells and incubated for 
overnight at 4°C.  After 5 washes, 100 μl horse radish peroxidase (HRP)-conjugated goat 
anti-mouse IgG (1:1000) (Merck, Darmstadt, Germany) was added to each well and incubated 
for 1 hour at room temperature, and then washed five times with 0.05% Tween-20-PBS.  For 
color development, TMB One Solution (Promega, Madison, WI, USA) was used and prepared 
according to the manufacturer's instructions.  The reaction was then stopped at 15 min by the 
addition of 50 μl of 1N HCl.  Absorbance was read at 490 nm using a microplate reader 
(Multiskan Spectrum; Thermo Fisher Scientific, Inc., Waltham, MA, USA).  
Antigen-specific IgG1, IgG2a, IgG2b, and IgG3 were also assayed using anti-mouse IgG1-, 
2a-, 2b-, and IgG3-HRP-conjugated antibodies (Abcam, Cambridge, MA) as described above.  
 
Statistical Analysis 
 Multiple comparisons among groups were made by Scheffe’s test.  Statistical 






Physicochemical properties of vaccines 
 The size and ζ-potential of the complexes were evaluated (Fig. 2).  OVA had 162.3 ± 4.5 
nm particle size and -25.2 ± 6.2 mV ζ-potential, as shown in Fig. 2.  Addition of BK 
increased ζ-potentials and reached a plateau at a weight ratio of 1:0.2.  OVA/BK complexes 
with a weight ratio of 1:0.1 aggregated and increased their particle size; however, stable 
cationic particles were formed on the nanoscale at a weight ratio greater than 1:0.2 (Figs. 2A 
and 2B).  We therefore added γ-PGA to OVA/BK complexes with a weight ratio of 1:0.2.  
 The addition of γ-PGA also aggregated OVA/BK complex at a charge ratio of 1:0.2:0.1; 
however, this dose-dependently decreased ζ-potentials, which reached a plateau at 1:0.2:0.2, 
and then stable anionic OVA/BK/γ-PGA complexes were formed on a nanoscale (Figs. 2C 
and 2D). Therefore, the OVA/BK/γ-PGA complex at a charge ratio of 1:0.2:0.2 was used as a 
nano-vaccine throughout the present study.   
 
Cellular uptake of the vaccine 
 OVA and OVA/BK/γ-PGA complex containing RITC-labeled OVA were added to the 
dendritic cell line DC2.4 cells and their uptake was determined using fluorescent microscopy, 
as shown in Fig. 3.  RITC-labeled OVA was taken up by DC2.4 cells a little (arrow); 




Determination of OVA-specific IgG in serum 
 OVA, the vehicle, and OVA/BK/γ-PGA complex were administrated into mice four times 
and OVA-specific IgG was determined by ELISA (Fig. 4).  Addition of OVA increased the 
IgG value in mice; however, OVA-specific IgG was not detected in mice administrated with 
the vehicle.  On the other hand, OVA/BK/γ-PGA complex showed significantly higher IgG 
production than the control, OVA, and the vehicle (P < 0.01). 
 
Assessment of IgG subtypes 
 OVA-specific IgG subtypes, such as IgG1, IgG2a, IgG2b, and IgG3, were also 
determined as shown in Fig. 5.  OVA significantly increased only IgG1 over the control (P < 
0.01).  At the same time, OVA/BK/γ-PGA complex showed significantly higher antibody 
induction than the control, OVA, and vehicle in all subtypes (P < 0.05).   
 
Impletion effect of the complexes on tumor 
 The OVA, vehicle, and OVA/BK/γ-PGA complex were administrated into mice four 
times and the immune response against OVA-expressing tumor cell line E.G7 cells was 
evaluated (Fig. 6).  OVA and vehicle did not inhibit tumor growth.  On the other hand, 
OVA/BK/γ-PGA complex significantly inhibited tumor growth (P < 0.01) and rejected the 
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tumor cells completely.   
 After administration of the tumor cells, the survival time of mice was also observed, as 
shown in Fig. 7.  The OVA and vehicle did not improve survival time; however, mice treated 




 Cancer vaccine is a treatment that enhances the patient’s own immune system.  The 
APCs most suitable for cancer vaccine are reported to be dendritic cells (DCs), which play a 
central role in the initiation and regulation of tumor-specific immune responses as they are 
endowed with unique potential to activate anti-tumor effector T and B lymphocytes, and are 
capable of promoting natural killer (NK) T cells or NK cell activation (15, 16).   
 In a previous study, it has been discovered that a complex coated by γ-PGA could 
improve the cellular uptake of dendritic cells and reported that malaria DNA vaccine coated 
with γ-PGA improved immune induction against malaria (13).  The γ-PGA, however, is an 
anionic polymer and did not interact with proteins with anionic or neutral charges; therefore, 
in the preliminary experiment, we explored the effects of cationic compounds, such as 
polyethylenimine, polylysine, polyarginine, chitosan, protamine, and BK for adhesive γ-PGA 
on antigen protein.  Among them, we found that the addition of BK could form stable 
γ-PGA-coated nanoparticles with an anionic surface.  We therefore investigated the utility of 
γ-PGA-coated nanoparticles for an effective and safe cancer vaccine.  We used OVA as a 
model of antigen protein and constructed OVA/BK/γ-PGA complex as a novel vaccine in this 
experiment. 
 We first evaluated the physicochemical properties of complexes with various weight 
ratios of OVA, BK, and γ-PGA (Fig. 2).  The addition of BK to OVA changed the anionic 
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charge of OVA to a stable cationic charge.  Furthermore, γ-PGA changed the cationic surface 
charge of OVA/BK complex into an anionic charge once more, and a stable anionic complex, 
OVA/BK/γ-PGA complex was formed.   These results showed OVA in the core and γ-PGA 
on the surface.   
 We have already demonstrated that γ-PGA coating enhanced the cellular uptake by a 
γ-PGA-specific receptor-mediated pathway regardless of their anionic surface charges (11).  
We therefore added OVA and OVA/BK/γ-PGA complex to the dendritic cell line, DC2.4 cells, 
and the uptake of OVA was monitored as shown in Fig. 3.  The γ-PGA coating enhanced the 
uptake of OVA in the cells.  These results indicated that OVA/BK/γ-PGA complex would 
induce a high immune response under in vivo conditions.   
 For assessment of the in vivo immune induction effect of the OVA/BK/γ-PGA complex, 
OVA, vehicle, and OVA/BK/γ-PGA complex were administrated into mice and OVA-specific 
IgG induction was evaluated (Fig. 4).  OVA slightly induced IgG; however, the 
OVA/BK/γ-PGA complex significantly improved IgG induction over the control, OVA, and 
vehicle (P < 0.01).  The γ-PGA on the surface of OVA/BK/γ-PGA complex should deliver 
OVA to the APCs and improve the immune induction effects.  
 IgG subtypes such as IgG1, IgG2a, IgG2b, and IgG3 were also determined, as shown in 
Fig. 5.  OVA showed significantly higher IgG1 than the control (P < 0.01).  IgG1 and 
IgG2b were reported to be Th2-type immunoglobulins and OVA could induce only 
Th2-mediated humoral immune responses (17).  On the other hand, OVA/BK/γ-PGA 
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complex markedly improved not only Th2-type immunoglobulins (IgG1 and IgG2b) but also 
Th1-type immunoglobulins (IgG2a and IgG3).  These results indicated that the 
OVA/BK/γ-PGA complex is able to induce both humoral immune responses and cellular 
immune responses, suggesting its suitability as a cancer vaccine.   
 Therefore, the antitumor effects were evaluated in mice immunized with OVA/BK/γ-PGA 
complex as shown in Fig. 6.  OVA and the vehicle did not inhibit the tumor growth of E.G7 
cells, which expresses OVA regularly.  At the same time, OVA/BK/γ-PGA complex 
completely inhibited tumor growth and rejected E.G7 cells.  Furthermore, the survival time 
of tumor-bearing mice was observed (Fig. 7).  Mice administrated OVA or the vehicle had 
died by 40 days after tumor inoculation.  The OVA/BK/γ-PGA complex-treated mice, 
however, did not die until 100 days.  Those marked anti-tumor effects could be explained by 
the high Th1-type immune induction of OVA/BK/γ-PGA complex.  Furthermore, the 
OVA/BK/γ-PGA complex-treated mice did not have hair loss and weight loss after 100 days, 
suggesting little chronic toxicity. 
 γ-PGA is biocompatible and biodegradable polymer produced by microbial species 
typified by Bacillus subtilis without immunoreactions and inflammatory reactions (18, 19).  
BK is a safe quaternary ammonium compound that has been in clinical use since 1935 as an 
antimicrobial additive used to maintain the sterility of a variety of prescription and 
over-the-counter products (20, 21).  These reports support the safety of the OVA/BK/γ-PGA 




 In this experiment, we constructed a novel cancer vaccine, OVA/BK/γ-PGA complex, for 
effective and safe cancer therapy.  The vaccine markedly improved Th1-type and Th2-type 
immune induction against OVA as a model antigen protein.  A marked antitumor effect was 
observed by the OVA/BK/γ-PGA complex.  This technology could be applied to most 
antigen proteins and peptides.  We propose that this vaccine delivery system should be a 
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Fig. 2. Size (A and C) and ζ-potentials (B and D) of the complexes. 
 To construct the OVA/BK complex, various charge ratios of BK were added to the OVA 
and their sizes (A) and ζ-potentials (B) were evaluated.  γ-PGA was added to OVA/BK 
complex with a charge ratio of 1:0.2, and the sizes (C) and ζ-potentials (D) of 
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Fig. 3. Fluorescent microscopy image of DC2.4 cells exposed to OVA and OVA/BK/γ-PGA 
complex containing RITC-labeled OVA. 
 DC2.4 cells were exposed to the vaccines for 2 hours and then the uptake of 




























Fig. 4. Evaluation of OVA-specific IgG induction 
 Mice were administrated with OVA, vehicle, and OVA/BK/γ-PGA complex weekly, four 
times.  Two weeks after the last administration, blood samples were collected from the mice 
and OVA-specific IgG induction was evaluated by ELISA.  Each bar represents the mean ± 




Fig. 5. Assessments of OVA-specific IgG subtypes 
 Mice were administrated with OVA, vehicle, and OVA/BK/γ-PGA complex weekly, four 
times.  Two weeks after the last administration, blood samples were collected from the mice 
and OVA-specific IgG1, IgG2a, IgG2b, and IgG3 inductions were evaluated by ELISA.  
Each bar represents the mean ± S.E. of four-five mice.  *: P < 0.05, **: P < 0.01 vs control, 
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Fig. 6. Tumor growth of E.G7 cell-bearing mice administrated with OVA, vehicle, and 
OVA/BK/γ-PGA complex. 
 Mice were administrated the OVA, vehicle, and OVA/BK/γ-PGA complex weekly, 4 
times. Two weeks after the last administration, E.G7 cells were administrated to mice 
intradermally and tumor growth was monitored.  Data are the mean ± S.E. of four-five mice.  
**: P < 0.01. 
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Fig. 7. Survival times of E.G7 cell-bearing mice administrated with OVA, vehicle, and 
OVA/BK/γ-PGA complex. 
 Mice were administrated the OVA, vehicle, and OVA/BK/γ-PGA complex weekly, 4 
times. Two weeks after the last administration, E.G7 cells were administrated to mice 
intradermally and survival was monitored.  Data are the mean ± S.E. of four-five mice.  **: 
P < 0.01. 
 
